Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618605 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00618605 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants.
The verdict
NCT00618605, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response. The purpose of this study is to determine the safety of and immune response to an adenovirus serotype HIV vaccine in HIV uninfected adults.
Interventions
- BIOLOGICAL Ad26.ENVA.01 HIV-1 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618605
The ClinicalTrials.gov registry entry for NCT00618605 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad26.ENVA.01 HIV-1 vaccine is the first listed.
NCT00618605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618605 about?
NCT00618605 is a clinical study titled "Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults". Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response. The purpose of this study is to determine the safety of and immune response to an adenovirus serotype HIV vaccine in HIV uninfec...
What is the current status of trial NCT00618605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00618605?
The interventions under investigation include: Ad26.ENVA.01 HIV-1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00618605?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.